-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
-
-
-
-
-
-
Cullinan Therapeutics (CGEM) Reports Positive Initial Data from Phase 2b REZILIENT1 Study of Zipalertinib
-
-
66,683 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

